Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy.
Nanoparticle-Loaded Polarized-Macrophages for Enhanced Tumor Targeting and Cell-Chemotherapy.
复制标题
纳米颗粒负载的极化巨噬细胞用于增强肿瘤靶向和细胞化疗
DOI：
10.1007/s40820-020-00531-0
复制
发表时间：
2020-10-27
影响因子：
26.6
通讯作者：
Zhang N
中科院分区：
文献类型：
--
作者：
Hou T;Wang T;Mu W;Yang R;Liang S;Zhang Z;Fu S;Gao T;Liu Y;Zhang N
细胞治疗是一种很有前途的癌症治疗策略。然而，由于肿瘤微环境的复杂性和免疫抑制性，其治疗效率仍然有限。本研究提出了“细胞-化疗”策略以提高抗肿瘤疗效。M1型巨噬细胞是一种兼具免疫原性和靶向性的治疗性免疫细胞，其携带索拉非尼脂质纳米粒（M1/SLNPs）。M1型巨噬细胞既作为治疗工具提供免疫治疗，又作为递送容器将SF靶向递送到肿瘤组织用于化疗。通过使用脂多糖极化巨噬细胞获得M1型巨噬细胞，并且通过将M1型巨噬细胞与SLNP孵育获得M1/SLNP。与SLNP相比，M1/SLNP的肿瘤蓄积增加（p< 0.01），证明M1/SLNP能增强SF的肿瘤靶向性。M1/SLNP治疗后M1型巨噬细胞与M2型巨噬细胞的比例增加，肿瘤组织中CD 3 + CD 4 +T细胞和CD 3 + CD 8 +T细胞数量增加，表明M1/SLNP可缓解免疫抑制性肿瘤微环境。M1/SLNP组的肿瘤体积显著小于SLNP组（p< 0.01），表明M1/SLNP显示出增强的抗肿瘤疗效。因此，M1/SLNP作为一种结合细胞治疗和靶向化疗的新型细胞化疗策略显示出巨大的潜力。
Cell therapy is a promising strategy for cancer therapy. However, its therapeutic efficiency remains limited due to the complex and immunosuppressive nature of tumor microenvironments. In this study, the “cell-chemotherapy” strategy was presented to enhance antitumor efficacy. M1-type macrophages, which are therapeutic immune cells with both of immunotherapeutic ability and targeting ability, carried sorafenib (SF)-loaded lipid nanoparticles (M1/SLNPs) were developed. M1-type macrophages were used both as therapeutic tool to provide immunotherapy and as delivery vessel to target deliver SF to tumor tissues for chemotherapy simultaneously. M1-type macrophages were obtained by polarizing macrophages using lipopolysaccharide, and M1/SLNPs were obtained by incubating M1-type macrophages with SLNP. Tumor accumulation of M1/SLNP was increased compared with SLNP (p< 0.01), which proved M1/SLNP could enhance tumor targeting of SF. An increased ratio of M1-type macrophages to M2-type macrophages, and the CD3+CD4+T cells and CD3+CD8+T cell quantities in tumor tissues after treatment with M1/SLNP indicated M1/SLNP could relieve the immunosuppressive tumor microenvironments. The tumor volumes in the M1/SLNP group were significantly smaller than those in the SLNP group (p< 0.01), indicating M1/SLNP exhibited enhanced antitumor efficacy. Consequently, M1/SLNP showed great potential as a novel cell-chemotherapeutic strategy combining both cell therapy and targeting chemotherapy.
登录
查看更多内容
DOI：
10.1016/j.jconrel.2016.07.018
发表时间：
2016-10-28
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Lee S;Kivimäe S;Dolor A;Szoka FC
通讯作者：
Szoka FC
影响因子：
8.4
作者：
Evans MA;Huang PJ;Iwamoto Y;Ibsen KN;Chan EM;Hitomi Y;Ford PC;Mitragotri S
通讯作者：
Mitragotri S
影响因子：
17.1
作者：
Fischbach MA;Bluestone JA;Lim WA
通讯作者：
Lim WA
影响因子：
7.3
作者：
Elahi R;Khosh E;Tahmasebi S;Esmaeilzadeh A
通讯作者：
Esmaeilzadeh A
影响因子：
19
作者：
Conde J;Bao C;Tan Y;Cui D;Edelman ER;Azevedo HS;Byrne HJ;Artzi N;Tian F
通讯作者：
Tian F